Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors
Aims: Obesity is a significant problem for patients taking atypical antipsychotics. There were two aims of our study. The first aim was to compare the prevalence of overweight and obesity between children and adolescents with autism spectrum disorder (ASD) treated with risperidone with the general p...
Main Authors: | Natchaya Vanwong, Nattawat Ngamsamut, Nopphadol Nuntamool, Yaowaluck Hongkaew, Rattanaporn Sukprasong, Apichaya Puangpetch, Penkhae Limsila, Chonlaphat Sukasem |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.565074/full |
Similar Items
-
Pharmacogenomic study reveals new variants of drug metabolizing enzyme and transporter genes associated with steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in Thai autism spectrum disorder patients
by: Sadeep Medhasi, et al.
Published: (2016-12-01) -
Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
by: Yaowaluck Hongkaew, et al.
Published: (2021-10-01) -
CYP2D6 polymorphisms and their influence on risperidone treatment
by: Puangpetch A, et al.
Published: (2016-12-01) -
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
by: Yaowaluck Hongkaew, et al.
Published: (2021-02-01) -
Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
by: Hongkaew Y, et al.
Published: (2015-01-01)